Department of Pharmacology, Clinical Pharmacology, Sri Aurobindo Medical College & PG Institute, Sri Aurobindo University, Indore, Madhya Pradesh, India

*Corresponding author: Mohammad Nadeem Khan, Department of Pharmacology, Clinical Pharmacology, Sri Aurobindo Medical College & PG Institute, Sri Aurobindo University, Indore, Madhya Pradesh, India, Phone: 9303362451, Email: [email protected]

Received Date: June 11, 2024

Published Date: July 02, 2024

Citation: Khan MN. (2024). Retention Challenges in New Medicinal Drug Clinical Trial for a Non-Small Cell Lung Cancer Patient with Bone Metastasis: A Case Report. Mathews J Case Rep. 9(6):170.

Copyrights: Khan MN. © (2024).

ABSTRACT

Retention of patients in clinical trials is essential for generating reliable and valid data, particularly in oncology where patient populations face significant health challenges. Advanced non-small cell lung cancer (NSCLC) with bone metastasis is a severe condition characterized by complex symptomatology and rapid disease progression. These factors pose unique challenges to patient retention in clinical trials. This case report examines the specific retention issues faced by a 62-year-old male patient with advanced NSCLC and bone metastasis in a Phase II clinical trial for a novel anti-cancer drug. The patient encountered multiple barriers, including severe pain, adverse treatment effects, psychological distress, logistical difficulties, and inadequate support systems, leading to his eventual withdrawal from the trial. This report provides a detailed discussion of these challenges and proposes comprehensive strategies to address them, such as enhanced pain and symptom management, proactive side effect mitigation, psychosocial support services, flexible trial designs, and robust patient and caregiver support networks. By implementing these strategies, clinical trials can improve retention rates, thereby ensuring the collection of high-quality data and advancing the development of effective cancer treatments.

Keywords: Non-Small Cell Lung Cancer (NSCLC), Bone Metastasis, Pain Management, Psychosocial Support, Novel Anti-Cancer Drug.